1 / 29

M. Valgimigli University of Ferrara Italy

FOURTH INTERNATIONAL SYMPOSIUM ON STEM CELL THERAPY AND APPLIED CARDIOVASCULAR BIOLOGY. Autologous bone marrow stem cell mobilization Induced by G-CSF after MI. M. Valgimigli University of Ferrara Italy. Madrid, 26°April 2007. Direct Inoculation. The New Paradigm?.

bridie
Download Presentation

M. Valgimigli University of Ferrara Italy

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. FOURTH INTERNATIONAL SYMPOSIUM ON STEM CELL THERAPY AND APPLIED CARDIOVASCULAR BIOLOGY Autologous bone marrow stem cell mobilization Induced by G-CSF after MI M. Valgimigli University of Ferrara Italy Madrid, 26°April 2007

  2. Direct Inoculation

  3. The New Paradigm? The “NO TOUCH” policy

  4. CD 34+ in AMI Patients *: p<0,01 vs. day 1 Valgimigli M et al.

  5. 200 µg/kg/day SCF 50 µg/kg/dayG-CSF 6 mice Splenectomized Euthanized 27 dys later 3 dys 2 wks 5 dys Coronary Ligation Mobilized bone marrow cells repair the infarcted heart, improving survival Orlic D, PNAS 2001

  6. G-CSF: the ideal candidate • Dose-dependent BM stem cells mobilisizer • Safety established on healthy donors • Reassuring long-term data available • However: • Platelet activation with shortening of bleeding time* • Fibrinogen and FVIII protein C and S* • Sporadical occurence of AMI in healthy donors *:Bone marrow transplantation 98; 22: 1087

  7. Study Flow-chart CD34+; CD34-CD133-KDR+, e-CFU Hb, WBC, PLT, urate, ESR, LDH, GT, AP, CRP Baseline 10 d 3° 4° 7 d 6 d 14 d 1° 2° G-CSF 5 µg/kg/day or placebo Single blind study Hospital admission Discharge 3 months 6 months ASA; clopidogrel, UFH GP IIb/IIIa inhibitors 4 days Primary PCI if eligible Deferred PCI if eligible 99mTc-sestamibi (740 MBq), gated-SPECT

  8. Lancet 2004; 363: 751 • Estimated sample size: 60 pts (20 per group) • Enrolment prematurely terminated for safety concerns about restenosis • Restenosis • 71% Cell infusion • 66% G-CSF

  9. Study Flow-chart Angiographic Follow-up CD34+; CD34-CD133-KDR+, e-CFU Hb, WBC, PLT, urate, ESR, LDH, GT, AP, CRP Baseline 10 d 3° 4° 7 d 6 d 14 d 1° 2° G-CSF 5 µg/kg/day or placebo Single blind study Hospital admission Discharge 3 months 6 months ASA; clopidogrel, UFH GP IIb/IIIa inhibitors 4 days Primary PCI if eligible Deferred PCI if eligible 99mTc-sestamibi (740 MBq), gated-SPECT

  10. and Angiographic Use of G-CSF during AMI to Enhance BMSC in HumansClinical Safety Profile • 20 pts out of 47 screened with AMI • 3 pts per group not treated with 1° PCI due to late presentation, subsequently 1 pt per group underwent deferred PCI for evidence of myocardial viability in the infarcted area • Syntoms Onset to G-CSG: • 37±265 hours (3-265) in the whole population • 16±66 hours (3-61) in those submitted to pPCI Valgimigli et al. EHJ 2005;26: 1838–1845

  11. G-CSF administration during MI to enhance BMSC mobilisation Valgimigli et al. EHJ 2005;26: 1838–1845

  12. G-CSF Impact on LV function at Gated-SPECT

  13. G-CSF Safety Issues • The drug was well tolerated-No complains-No arrhythmic events • 1/8 in placebo group and 0/8 in G-CSF developed binary restenosis Valgimigli et al. EHJ 2005;26: 1838–1845

  14. G-CSF in AMI

  15. G-CSF in AMI G-CSF Group P=0.71

  16. G-CSF in AMI -4 +6

  17. G-CSF in AMI

  18. G-CSF in AMI

  19. G-CSF in AMI P=0.035 P=0.007 n.s.

  20. G-CSF in AMI

  21. G-CSF in AMI P=ns Change in EF at 30 days (%)

  22. G-CSF in AMI

  23. G-CSF in AMI • Timing of treatment with respect to onset of symptoms

  24. G-CSF in AMI • Targeting the proper patient population • Severe LV function impairment • Anterior wall MI • Suboptimal mechanical reperfusion No data beyond 30 days 12 pts G-CSF vs. 6 controls

  25. Rigenera Study Courtesy of Leone AM. • 14 G-CSF vs. 27 controls • Anterior MI with EF <50% after 5 days LV end diastolic volume (ml)

  26. Rigenera Study Courtesy of Leone AM. • 14 G-CSF vs. 27 controls • Anterior MI with EF <50% after 5 days

  27. G-CSF and Binary restenosissystematic review of the literature Ince et al. submitted

  28. Individual patient data meta-analysis Ince et al. submitted

  29. Conclusions • G-CSF administration in acute MI is feasible • No REAL concern regarding clinical and ANGIOGRAPHIC safety profile • The effect of this treatment on LV function improvement remains unclear The time has arrived for a multicenter RCT

More Related